Hal Allergy
Netherlands - LeidenBiotechnology
Focus: Hal Allergy is a Dutch biotech focused on immunotherapy treatments for allergic diseases, operating from Leiden with a publicly traded status since 2020. The company spans sublingual immunotherapy, recombinant allergen extracts, and food allergy programs across multiple indications.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Hal Allergy
AI assessmentNot HiringNo open roles listed right now. Follow Hal Allergy to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Hal Allergy's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Help build intelligence for Hal Allergy
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.